Results 281 to 290 of about 521,269 (357)

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Irgm1 Restrains CD8⁺ T Cell Cytokine Production and Apoptosis via Cell-Extrinsic Regulation of Type I Interferon Signaling. [PDF]

Eur J Immunol
Molloy CT, Alwarawrah Y, Cohen JA, Fee BE, Whitmire JK, Taylor GA, MacIver NJ.   +6 more
europepmc   +1 more source

One‐Step Glycoengineering of NK Cells With High‐Affinity Siglec Ligands for Cancer Immunotherapy

Advanced Science, EarlyView.
This study develops an engineered NmCSS enzyme with improved activity for bulky group modified sialic acids, enabling efficient synthesis of structurally diverse sialoside analogs in a single step. Glycan microarray screening identified Siglec high‐affinity ligands, which were incorporated onto natural killer (NK) cells via a one‐pot enzymatic system ...
Shuai Hu, Ben Huang, Lingyan Wang, Qiang Guo, Cuiping Jiang, Ruicheng Qi, Shuyao Wang, Lin‐Tai Da, Wenjie Peng   +8 more
wiley   +1 more source

Identification of Histone Deacetylase Inhibitor Targeting Type I Interferon and B Cell Abnormalities in Systemic Lupus Erythematosus. [PDF]

Arthritis Rheumatol
Hirayama T, Konaka H, Kato Y, Shibahara T, Nishizawa C, Tsujimoto K, Park J, Itotagawa E, Jo T, Nishide M, Nishida S, Shima Y, Narazaki M, Aoki W, Ishii KJ, Takamatsu H, Kumanogoh A.   +16 more
europepmc   +1 more source

Exosomal transmission of non-cytopathic bovine viral diarrhea virus facilitates persistent infection by evading antibody neutralization and antagonizing type I interferon response

Xu, Yigang
openalex   +1 more source

CRISPR/Cas9‐Based Vanadium MXene‐Free Radical Spatiotemporally Controlled Nanoreactor for Photothermal‐Induced Multi‐Effect Synergistic Antitumor Therapy

Advanced Science, EarlyView.
In this study, a MXene‐based V4C3 nanoplatform, VARH, was constructed, which achieved a photothermal conversion efficiency of 44.21% in the NIR‐II window. This platform integrated photothermal therapy, chemodynamic therapy, and thermodynamic therapy with CRISPR/Cas9‐mediated heat shock protein 90 knock‐out technology.
Zi‐Jian Huang, Feng‐Ming Li, Yi‐Fan Tu, Ke‐Ke Feng, Cheng‐Lei Li, Shi‐Cheng Tian, Yong‐Shan Hu, Jing‐Wei Shao, Zhen‐Hua Liu   +8 more
wiley   +1 more source

RND3 restricts encephalomyocarditis virus replication by promoting IKKε ubiquitination and type I interferon production. [PDF]

Microbiol Spectr
Ma P, Wang Z, Liu Z, Xie Q, Liu T, Li L.
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Type I interferon production in myeloid cells is regulated by factors independent of Ptpn22. [PDF]

Immunohorizons
Barnes JR, Shaikh AF, Bevis AM, Cockerham TR, Orozco RC.   +4 more
europepmc   +1 more source

New roles for the major human 3\u27–5\u27 exonuclease TREX1 in human disease [PDF]

, 2008
Atkinson, John P, Kavanagh, David, Kothari, Parul H, Liszewski, M Kathryn, Richards, Anna, Shaikh, Aisha, Spitzer, Dirk   +6 more
core   +1 more source